Posted in Antibodies, Assay Kits, Biology Cells, cDNA, Clia Kits, Culture Cells, Devices, DNA, DNA Templates, DNA Testing, Elisa Kits, Enzymes, Equipments, Exosomes, Gels, Isotypes, Medium & Serums, NATtrol, Panel, Particles, PCR, Pcr Kits, Peptides, Reagents, Recombinant Proteins, Ria Kits, RNA, Test Kits, Vector & Virus, Western Blot
Top VHL Recombinant Protein For Human
Von Hippel-Lindau (VHL) Protein Antagonist VH298 Improves Wound Therapeutic in Streptozotocin-Induced Hyperglycaemic Rats by Activating Hypoxia-Inducible Issue- (HIF-) 1 Signalling.
The aim of the current analysis is to analyze the results of the VHL protein antagonist, VH298, on purposeful actions of fibroblasts and vascular endothelial cells and the results on the wound therapeutic course of in a streptozotocin-induced hyperglycaemic rat mannequin.
Strategies
HIF-1α and hydroxy-HIF-1α protein ranges in VH298-treated rat fibroblasts (rFb) had been measured by immunoblotting, rFb proliferation was detected by the CCK-Eight assay, and mRNA ranges of associated genes had been measured by quantitative RT-PCR. In vitro wound therapeutic was simulated by the scratch take a look at; angiogenesis was measured by the human umbilical vein endothelial cell (hUVEC) tube formation assay. VH298 or PBS was regionally injected into wounds in rat fashions with streptozotocbd tissues had been harvested, and haematoxylin-eosin (HE) and Masson trichrome staining and immunohistochemical processes had been carried out.
Human Von Hippel Lindau Tumor Suppressor (vHL) ELISA Equipment
Outcomes
HIF-1α and hydroxy-HIF-1α ranges elevated in VH298-treated rFb, in a time- and dose-dependent method. Thirty micromolar VH298 may considerably enhance cell proliferation, angiogenesis, and gene expression of sort I collagen-αα
Conclusions
Taken collectively, VH298 activated the HIF-1 signalling pathway by stabilizing each HIF-1α and hydroxy-HIF-1α. VH298 enhanced rFb capabilities, promoted hUVEC angiogenesis, and accelerated wound therapeutic within the rat mannequin mimicking diabetes mellitus.
Rat Von Hippel Lindau Tumor Suppressor (vHL) ELISA Equipment

Human Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
RD-vHL-Hu-48Tests |
Reddot Biotech |
48 Tests |
EUR 557 |
Human Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
RD-vHL-Hu-96Tests |
Reddot Biotech |
96 Tests |
EUR 775 |
Rat Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
RD-vHL-Ra-48Tests |
Reddot Biotech |
48 Tests |
EUR 557 |
Rat Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
RD-vHL-Ra-96Tests |
Reddot Biotech |
96 Tests |
EUR 775 |
Human Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
RDR-vHL-Hu-48Tests |
Reddot Biotech |
48 Tests |
EUR 583 |
Human Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
RDR-vHL-Hu-96Tests |
Reddot Biotech |
96 Tests |
EUR 811 |
Rat Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
RDR-vHL-Ra-48Tests |
Reddot Biotech |
48 Tests |
EUR 583 |
Rat Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
RDR-vHL-Ra-96Tests |
Reddot Biotech |
96 Tests |
EUR 811 |
VHL antibody |
70R-9757 |
Fitzgerald |
50 ug |
EUR 467 |
Description: Affinity purified rabbit polyclonal VHL antibody |
VHL antibody |
70R-34605 |
Fitzgerald |
100 ug |
EUR 327 |
Description: Purified Rabbit polyclonal VHL antibody |
VHL Antibody |
AF6292 |
Affbiotech |
200ul |
EUR 304 |
Description: VHL Antibody detects endogenous levels of total VHL. |
VHL antibody |
10R-1029 |
Fitzgerald |
100 ul |
EUR 316 |
Description: Mouse monoclonal VHL antibody |
VHL Antibody |
DF6104 |
Affbiotech |
200ul |
EUR 304 |
Description: VHL Antibody detects endogenous levels of total VHL. |
VHL Antibody |
1-CSB-PA060067 |
Cusabio |
|
|
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC:1/100-1/300.ELISA:1/40000 |
VHL Antibody |
1-CSB-PA071125 |
Cusabio |
|
|
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:2000-1:5000, WB:1:500-1:2000, IHC:1:25-1:100 |
VHL Antibody |
CSB-PA025852KA01HU- |
Cusabio |
|
EUR 335 |
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:2000, IHC:1:50-1:200 |
VHL Antibody |
CSB-PA025852KA01HU-100ul |
Cusabio |
100ul |
EUR 389 |
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:2000, IHC:1:50-1:200 |
VHL Antibody |
1-CSB-PA876839 |
Cusabio |
|
|
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC-p:1:50-300, ELISA:1:10000-20000 |
VHL Antibody |
1-CSB-PA991849 |
Cusabio |
|
|
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:10000, IHC:1:50-1:200 |
VHL Antibody |
32075-100ul |
SAB |
100ul |
EUR 252 |
VHL Polyclonal Antibody |
ES7499-100ul |
ELK Biotech |
100ul |
EUR 279 |
Description: A Rabbit Polyclonal antibody against VHL from Human/Mouse/Rat. This antibody is tested and validated for IHC, WB, ELISA |
VHL Polyclonal Antibody |
ES7499-50ul |
ELK Biotech |
50ul |
EUR 207 |
Description: A Rabbit Polyclonal antibody against VHL from Human/Mouse/Rat. This antibody is tested and validated for IHC, WB, ELISA |
VHL Polyclonal Antibody |
ES8746-100ul |
ELK Biotech |
100ul |
EUR 279 |
Description: A Rabbit Polyclonal antibody against VHL from Human. This antibody is tested and validated for IHC, WB, ELISA |
VHL Polyclonal Antibody |
ES8746-50ul |
ELK Biotech |
50ul |
EUR 207 |
Description: A Rabbit Polyclonal antibody against VHL from Human. This antibody is tested and validated for IHC, WB, ELISA |
VHL Polyclonal Antibody |
ABP60891-003ml |
Abbkine |
0.03ml |
EUR 158 |
|
Description: A polyclonal antibody for detection of VHL from Human. This VHL antibody is for IHC-P, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human VHL protein at amino acid sequence of 1-50 |
VHL Polyclonal Antibody |
ABP60891-01ml |
Abbkine |
0.1ml |
EUR 289 |
|
Description: A polyclonal antibody for detection of VHL from Human. This VHL antibody is for IHC-P, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human VHL protein at amino acid sequence of 1-50 |
VHL Polyclonal Antibody |
ABP60891-02ml |
Abbkine |
0.2ml |
EUR 414 |
|
Description: A polyclonal antibody for detection of VHL from Human. This VHL antibody is for IHC-P, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human VHL protein at amino acid sequence of 1-50 |
VHL Polyclonal Antibody |
ABP56500-003ml |
Abbkine |
0.03ml |
EUR 158 |
|
Description: A polyclonal antibody for detection of VHL from Human, Mouse, Rat. This VHL antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human VHL around the non-phosphorylation site of S68 |
VHL Polyclonal Antibody |
ABP56500-01ml |
Abbkine |
0.1ml |
EUR 289 |
|
Description: A polyclonal antibody for detection of VHL from Human, Mouse, Rat. This VHL antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human VHL around the non-phosphorylation site of S68 |
VHL Polyclonal Antibody |
ABP56500-02ml |
Abbkine |
0.2ml |
EUR 414 |
|
Description: A polyclonal antibody for detection of VHL from Human, Mouse, Rat. This VHL antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human VHL around the non-phosphorylation site of S68 |
VHL (pS68) Antibody |
abx219320-100ug |
Abbexa |
100 ug |
EUR 439 |
|
Anti-VHL antibody |
STJ26089 |
St John's Laboratory |
100 µl |
EUR 277 |
Description: Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. |
Anti-VHL antibody |
STJ98809 |
St John's Laboratory |
200 µl |
EUR 197 |
Description: Rabbit polyclonal to VHL. |
Anti-VHL antibody |
STJ96241 |
St John's Laboratory |
200 µl |
EUR 197 |
Description: Rabbit polyclonal to VHL. |
Human VHL Antibody |
32825-05111 |
AssayPro |
150 ug |
EUR 261 |
Anti-VHL antibody |
STJ113440 |
St John's Laboratory |
50 µl |
EUR 277 |
Description: Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. |
Anti-VHL antibody |
STJ113742 |
St John's Laboratory |
100 µl |
EUR 277 |
Description: Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. |
VHL Polyclonal Antibody |
46866-100ul |
SAB |
100ul |
EUR 252 |
VHL Polyclonal Antibody |
46866-50ul |
SAB |
50ul |
EUR 187 |
VHL Conjugated Antibody |
C32075 |
SAB |
100ul |
EUR 397 |
anti- VHL antibody |
FNab10175 |
FN Test |
100µg |
EUR 505.25 |
|
Description: Antibody raised against VHL |
VHL Dependent Expression of REDD1 and PDK3 Proteins in Clear-cell Renal Cell Carcinoma.
- Sporadic clear-cell renal cell carcinoma (ccRCC) is related with mutations within the VHL gene, upregulated mammalian goal of rapamycin (mTOR) exercise and glycolytic metabolism. Right here, we analyze the impact of VHL mutational standing on the expression stage of mTOR, eIF4E-BP1, AMPK, REDD1, and PDK3 proteins.
pGF-AP1-mCMV-EF1-Puro (293 secure cell line)
- Complete proteins had been remoted from 21 tumorous samples with biallelic inactivation, 10 with monoallelic inactivation and 6 tumors with a wild-type VHL (wtVHL) gene obtained from sufferers who underwent complete nephrectomy. The expressions of goal proteins had been assessed utilizing Western blot.Expressions of mTOR, eIF4EBP1 and AMPOkay had been VHL impartial.
- Tumors with monoallelic inactivation of VHL underexpressed REDD1 compared to wtVHL tumors (P = 0.042), tumors with biallelic VHL inactivation (P < 0.005) and management tissue (P = 0.004). Moreover, REDD1 expression was larger in tumors with VHL biallelic inactivation than in management tissue (P = 0.008). Solely in wt tumor samples PDK3 was overexpressed compared to tumors with biallelic inactivation of VHL gene (P = 0.012) and controls (P = 0.016). In wtVHL ccRCC, multivariate linear regression evaluation revealed that 97.4% of variability in PDK3 expression might be defined by variations in AMPK quantity.Expressions of mTOR, eIF4EBP1 and AMPK had been VHL impartial.
- Now we have proven for the primary time VHL dependent expression of PDK3 and we offer extra proof that VHL mutational standing impacts REDD1 expression in sporadic ccRCC.
Gene Knock-Out HR Concentrating on Vector w/Single Choice Marker (Blasticidin) and Destructive Choice (TK) Towards Random Integration
-
VHL sufferers (n = 339) had been recruited and grouped primarily based on mutation sorts: HIF-α binding web site missense (HM) mutations, non-HIF-α binding web site missense (nHM) mutations, and truncating (TR) mutations. Age-related dangers of VHL-associated tumors and affected person survival had been in contrast.
-
Missense mutations conferred an elevated danger of pheochromocytoma (HR = 1.854, p = 0.047) in contrast with truncating mutations. The danger of pheochromocytoma was decrease within the HM group than within the nHM group (HR = 0.298, p = 0.003) however was related between HM and TR teams (HR = 0.901, p = 0.810).
Human Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
RDR-vHL-Hu-48Tests |
Reddot Biotech |
48 Tests |
EUR 583 |
Human Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
RDR-vHL-Hu-96Tests |
Reddot Biotech |
96 Tests |
EUR 811 |
Gene Knock-Out HR Targeting Vector [MCS1-EF1?-RFP-T2A-Puro-pA-MCS2] |
HR110PA-1 |
SBI |
10 ug |
EUR 1023 |
|
Gene Knock-Out HR Targeting Vector [MCS1-EF1a-GFP-T2A-Puro-pA-MCS2] |
HR410PA-1 |
SBI |
10 ug |
EUR 1023 |
|
Gene Knock-Out HR Targeting Vector [MCS1-EF1a-RFP-T2A-Hygro-pA-MCS2] |
HR510PA-1 |
SBI |
10 ug |
EUR 1023 |
|
TARGATT? Knock-in iPSC Generation (Master Cell Line) |
AST-1100 |
Applied StemCell |
1 vial of 1X10^6 cells |
Ask for price |
Description: 6 month |
TARGATT? Knock-in Mouse Cell Line Generation Kit (Master Cell Line) |
AST-7001 |
Applied StemCell |
1 Kit |
Ask for price |
Description: 6 month |
Rat Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
DLR-vHL-Ra-48T |
DL Develop |
48T |
EUR 549 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Rat Von Hippel Lindau Tumor Suppressor (vHL) in samples from tissue homogenates or other biological fluids. |
Rat Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
DLR-vHL-Ra-96T |
DL Develop |
96T |
EUR 718 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Rat Von Hippel Lindau Tumor Suppressor (vHL) in samples from tissue homogenates or other biological fluids. |
Rat Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
RD-vHL-Ra-48Tests |
Reddot Biotech |
48 Tests |
EUR 557 |
Rat Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
RD-vHL-Ra-96Tests |
Reddot Biotech |
96 Tests |
EUR 775 |
Rat Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
RDR-vHL-Ra-48Tests |
Reddot Biotech |
48 Tests |
EUR 583 |
Rat Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit |
RDR-vHL-Ra-96Tests |
Reddot Biotech |
96 Tests |
EUR 811 |
Vhl 3'UTR Luciferase Stable Cell Line |
TU121762 |
ABM |
1.0 ml |
Ask for price |
VHL 3'UTR GFP Stable Cell Line |
TU078117 |
ABM |
1.0 ml |
EUR 1521 |
Vhl 3'UTR GFP Stable Cell Line |
TU171762 |
ABM |
1.0 ml |
Ask for price |
Vhl 3'UTR Luciferase Stable Cell Line |
TU223038 |
ABM |
1.0 ml |
Ask for price |
VHL 3'UTR Luciferase Stable Cell Line |
TU028117 |
ABM |
1.0 ml |
EUR 1521 |
Vhl 3'UTR GFP Stable Cell Line |
TU273038 |
ABM |
1.0 ml |
Ask for price |
TARGATT? Knock-in CHO Generation Kit (Master Cell Line) |
AST-1200 |
Applied StemCell |
1 Kit |
Ask for price |
Description: 12 month |
TARGATT? Knock-in HEK293 Generation Kit (Master Cell Line) |
AST-1300 |
Applied StemCell |
1 Kit |
Ask for price |
Description: 12 month |
293LTV Cell Line |
LTV-100 |
Cell Biolabs |
1 vial |
EUR 508 |
Description: The 293LTV Cell Line is derived from the parental 293 cells but selected for attributes that increase lentiviral production, including fimrer attachment and larger surface area. |
293AD Cell Line |
AD-100 |
Cell Biolabs |
1 vial |
EUR 461 |
Description: The 293AD Cell Line is derived from the parental 293 cells but selected for attributes that increase adenovirus production, including firmer attachment and larger surface area. |
293AAV Cell Line |
AAV-100 |
Cell Biolabs |
1 vial |
EUR 508 |
Description: The 293AAV Cell Line is derived from the parental 293 cells but selected for attributes that increase AAV production, including firmer attachment and larger surface area. |
293RTV Cell Line |
RV-100 |
Cell Biolabs |
1 vial |
EUR 508 |
Description: The 293RTV Cell Line is derived from the parental 293 cells but selected for attributes that increase retroviral production, including fimrer attachment and larger surface area. |
Basic HR Targeting Vector [MCS1-LoxP-MCS2-MCS3-pA-LoxP-MCS4] for Gene Knock-In/Out |
HR100PA-1 |
SBI |
10 ug |
EUR 938 |
|
T47D/GFP Cell Line |
AKR-208 |
Cell Biolabs |
1 vial |
EUR 572 |
Description: T47D/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line. |
A549/GFP Cell Line |
AKR-209 |
Cell Biolabs |
1 vial |
EUR 572 |
Description: A549/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line. |
HeLa/GFP Cell Line |
AKR-213 |
Cell Biolabs |
1 vial |
EUR 572 |
Description: HeLa/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line. |
NIH3T3/GFP Cell Line |
AKR-214 |
Cell Biolabs |
1 vial |
EUR 572 |
Description: NIH3T3/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line. |
Human VHL Antibody |
32825-05111 |
AssayPro |
150 ug |
EUR 261 |
Recombinant human VHL |
P2120 |
FN Test |
100ug |
Ask for price |
|
Description: Recombinant protein for human VHL |
Mouse pre-microRNA Expression Construct mir-293+294+295 |
MMIR-293-295-PA-CL |
SBI |
Bacterial Streak |
EUR 968 |
|
Microplate Swing-Out Centrifuge |
abx725026-1Unit |
Abbexa |
1 Unit |
EUR 1476 |
|
Clinical Swing-Out Centrifuge |
abx725027-1Unit |
Abbexa |
1 Unit |
EUR 1476 |
|
SKOV-3/Luc Cell Line |
AKR-232 |
Cell Biolabs |
1 vial |
EUR 572 |
Description: SKOV-3/Luc Cell Line stably expresses luciferase and otherwise exhibits the same characteristics of the parental cell line. |
MCF-7/Luc Cell Line |
AKR-234 |
Cell Biolabs |
1 vial |
EUR 572 |
Description: MCF-7/Luc Cell Line stably expresses luciferase and otherwise exhibits the same characteristics of the parental cell line. |
OVCAR-5/RFP Cell Line |
AKR-254 |
Cell Biolabs |
1 vial |
EUR 572 |
Description: OVCAR-5/RFP Cell Line stably expresses RFP and otherwise exhibits the same characteristics of the parental cell line. |
VHL sgRNA CRISPR Lentivector set (Human) |
K2611301 |
ABM |
3 x 1.0 ug |
EUR 339 |
Gene Knock-Out HR Targeting Vector w/Single Selection Marker (Blasticidin) and Negative Selection (TK) Against Random Integration |
HR720PA-1 |
SBI |
10 µg |
EUR 1145 |
|
VHL antibody |
70R-9757 |
Fitzgerald |
50 ug |
EUR 467 |
Description: Affinity purified rabbit polyclonal VHL antibody |
VHL antibody |
70R-34605 |
Fitzgerald |
100 ug |
EUR 327 |
Description: Purified Rabbit polyclonal VHL antibody |
VHL Antibody |
AF6292 |
Affbiotech |
200ul |
EUR 304 |
Description: VHL Antibody detects endogenous levels of total VHL. |
VHL antibody |
10R-1029 |
Fitzgerald |
100 ul |
EUR 316 |
Description: Mouse monoclonal VHL antibody |
VHL Antibody |
DF6104 |
Affbiotech |
200ul |
EUR 304 |
Description: VHL Antibody detects endogenous levels of total VHL. |
VHL Antibody |
1-CSB-PA060067 |
Cusabio |
|
|
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC:1/100-1/300.ELISA:1/40000 |
VHL Antibody |
1-CSB-PA071125 |
Cusabio |
|
|
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:2000-1:5000, WB:1:500-1:2000, IHC:1:25-1:100 |
VHL Antibody |
CSB-PA025852KA01HU- |
Cusabio |
|
EUR 335 |
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:2000, IHC:1:50-1:200 |
VHL Antibody |
CSB-PA025852KA01HU-100ul |
Cusabio |
100ul |
EUR 389 |
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:2000, IHC:1:50-1:200 |
VHL Antibody |
1-CSB-PA876839 |
Cusabio |
|
|
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC-p:1:50-300, ELISA:1:10000-20000 |
VHL Antibody |
1-CSB-PA991849 |
Cusabio |
|
|
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:10000, IHC:1:50-1:200 |
VHL Antibody |
32075-100ul |
SAB |
100ul |
EUR 252 |
pGF-AP1-mCMV-EF1-Puro (293 stable cell line) |
TR201a-p |
SBI |
>2 x 10^6 cells |
EUR 3263 |
|
pGF-CREB-mCMV-EF1-Puro (293 stable cell line) |
TR202a-p |
SBI |
>2 x 10^6 cells |
EUR 3263 |
|
pGF-EGR1-mCMV-EF1-Puro (293 stable cell line) |
TR204a-p |
SBI |
>2 x 10^6 cells |
EUR 3263 |
|
NF-kB/293/GFP-Luc Transcriptional Reporter Cell Line |
TR860A-1 |
SBI |
>2 x 10^6 cells |
EUR 3263 |
|
VHL Recombinant Protein (Human) |
RP034324 |
ABM |
100 ug |
Ask for price |
Human VHL shRNA Plasmid |
20-abx955082 |
Abbexa |
|
|
|
Gene Knock-Out HR Targeting Vector w/Dual Selection Markers (GFP+Puro) and Negative Selection (TK) Against Random Integration |
HR700PA-1 |
SBI |
10 µg |
EUR 1145 |
|
Gene Knock-Out HR Targeting Vector w/Dual Selection Markers (RFP+Hygro) and Negative Selection (TK) Against Random Integration |
HR710PA-1 |
SBI |
10 µg |
EUR 1145 |
|
Platinum-E Retroviral Packaging Cell Line, Ecotropic |
RV-101 |
Cell Biolabs |
1 vial |
EUR 920 |
Description: Conventional cells used for retrovirus packaging, such as those based on NIH3T3 cells, have limited stability and produce relatively low yields of retrovirus, mainly due to the poor expression of retroviral structure proteins (gag, pol and env) in the cells. The Platinum Retroviral Packaging Cell Lines are based on the 293T cell line. They exhibit longer stability and produce higher yields of retroviral structure proteins. Plat-E cells contain gag, pol and env genes, allowing retroviral packaging with a single plasmid transfection. |
Platinum-A Retroviral Packaging Cell Line, Amphotropic |
RV-102 |
Cell Biolabs |
1 vial |
EUR 920 |
Description: Conventional cells used for retrovirus packaging, such as those based on NIH3T3 cells, have limited stability and produce relatively low yields of retrovirus, mainly due to the poor expression of retroviral structure proteins (gag, pol and env) in the cells. The Platinum Retroviral Packaging Cell Lines are based on the 293T cell line. They exhibit longer stability and produce higher yields of retroviral structure proteins. Plat-A cells contain gag, pol and env genes, allowing retroviral packaging with a single plasmid transfection. |
Platinum-GP Retroviral Packaging Cell Line, Pantropic |
RV-103 |
Cell Biolabs |
1 vial |
EUR 920 |
Description: Conventional cells used for retrovirus packaging, such as those based on NIH3T3 cells, have limited stability and produce relatively low yields of retrovirus, mainly due to the poor expression of retroviral structure proteins (gag, pol and env) in the cells. The Platinum Retroviral Packaging Cell Lines are based on the 293T cell line. They exhibit longer stability and produce higher yields of retroviral structure proteins. Plat-GP cells contain the gag and pol genes required for retroviral packaging; an expression vector is co-transfected with a VSVG envelope vector. |
VHL sgRNA CRISPR Lentivector (Human) (Target 1) |
K2611302 |
ABM |
1.0 ug DNA |
EUR 154 |
VHL sgRNA CRISPR Lentivector (Human) (Target 2) |
K2611303 |
ABM |
1.0 ug DNA |
EUR 154 |
VHL sgRNA CRISPR Lentivector (Human) (Target 3) |
K2611304 |
ABM |
1.0 ug DNA |
EUR 154 |
PIK-293 |
E1KS2207 |
EnoGene |
5mg |
EUR 599 |
PIK-293 |
B2187-10 |
ApexBio |
10 mg |
EUR 440 |
Description: PIK-293 is a PI3K inhibitor, mostly for PI3K? with IC50 of 0.24 ?M, 500-, 100- and 50-fold less potent to PI3K?/?/?, respectively. |
PIK-293 |
B2187-25 |
ApexBio |
25 mg |
EUR 902 |
Description: PIK-293 is a PI3K inhibitor, mostly for PI3K? with IC50 of 0.24 ?M, 500-, 100- and 50-fold less potent to PI3K?/?/?, respectively. |
PIK-293 |
B2187-5 |
ApexBio |
5 mg |
EUR 270 |
Description: PIK-293 is a PI3K inhibitor, mostly for PI3K? with IC50 of 0.24 ?M, 500-, 100- and 50-fold less potent to PI3K?/?/?, respectively. |
IBC 293 |
B7069-10 |
ApexBio |
10 mg |
EUR 197 |
IBC 293 |
B7069-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 108 |
IBC 293 |
B7069-50 |
ApexBio |
50 mg |
EUR 669 |
Total Protein - Murine Embryonic Stem Cell Line D3 |
CBA-305 |
Cell Biolabs |
500 ?g |
EUR 345 |
Description: - Isolated from mouse ES-D3 cell line
- Presented as 500 µg at 1 mg/mL in NP-40 Solubilization Buffer
|
Gene Knock-Out HR Targeting Vector with TK selection [MCS1-LoxP-EF1?-GFP-T2A-Puro-P2A-hsvTK-pA-LoxP-MCS2] |
HR210PA-1 |
SBI |
10 ug |
EUR 1145 |
|
VHL Blocking Peptide |
AF6292-BP |
Affbiotech |
1mg |
EUR 195 |
-
Sufferers within the nHM group had the next danger of pheochromocytoma (HR = 3.447, p < 0.001) and decrease dangers of central nervous system hemangioblastoma (CHB) (HR = 0.700, p = 0.045), renal cell carcinoma (HR = 0.610, p = 0.024), and pancreatic tumor (HR = 0.382, p < 0.001) than these within the mixed HM and TR (HMTR) group.
-
Furthermore, nHM mutations had been independently related to better general survival (HR = 0.345, p = 0.005) and CHB-specific survival (HR = 0.129, p = 0.005) than HMTR mutations.
-
The modified genotype-phenotype correlation hyperlinks VHL gene mutation, substrate binding web site, and phenotypic range (penetrance and survival), and offers extra correct data for genetic counseling and pathogenesis research.